연구동향 분석

원저 : 중등도-중증의 한국인 건선 환자에서 Ustekinumab의 효과와 안전성에 관한 연구

박성민 ( Sung Min Park ) 김정민(Jeong-Min Kim) 김건욱 ( Gun Wook Kim ) 문제호 ( Je Ho Mun ) 송마가렛 ( Margaret Song ) 김훈수 ( Hoon Soo Kim ) 고현창 ( Hyun Chang Ko ) 김문범 ( Moon Bum Kim ) 김병수 ( Byung Soo Kim ) 2015년

논문상세정보
인용/피인용
' 원저 : 중등도-중증의 한국인 건선 환자에서 Ustekinumab의 효과와 안전성에 관한 연구' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • clinicalsetting
  • efficacy
  • psoriasis
  • safety
  • ustekinumab
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
812 0

0.0%

' 원저 : 중등도-중증의 한국인 건선 환자에서 Ustekinumab의 효과와 안전성에 관한 연구' 의 참고문헌

  • 경증 및 중등증 건선환자에서의 사이클로스포린 치료의 효능 및 안전성에 대한 후향적 연구
    이광준 대한피부과학회지 43 (12) : 1619 ~ 1625 [2005]
  • Psoriasis causes as much disability as other major medical diseases
    Rapp SR J Am Acad Dermatol 41 : 401 ~ 407 [1999]
  • Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years
    Kimball AB Br J Dermatol 166 : 861 ~ 872 [2012]
  • Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: Results from the PHOENIX 2study through 5 years of follow-up
    Langley RG Br J Dermatol 1111 : 13469 ~ [2014]
  • Interleukin-12, interleukin-23, and psoriasis: current prospects
    Torti DC J Am Acad Dermatol 57 : 1059 ~ 1068 [2007]
  • How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review
    Spuls PI J Invest Dermatol 130 : 933 ~ 943 [2010]
  • Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013
    Murray CJ Lancet 384 : 1005 ~ 1070 [2014]
  • Fitzpatrick’s dermatology in general medicine. 8th ed
    Gudjosson JE McGraw-Hill Professional : 197 ~ [2008]
  • Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
    Leonardi CL Lancet 371 : 1665 ~ 1674 [2008]
  • Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 2)
    Papp KA Lancet 371 : 1675 ~ 1684 [2008]
  • Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)
    Tsai TF J Dermatol Sci 63 : 154 ~ 163 [2011]
  • Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives
    Yeilding N Ann N Y Acad Sci 1222 : 30 ~ 39 [2012]
  • Detection and management of latent tuberculosis infections before biologic therapy for psoriasis
    Amerio P J Dermatolog Treat 24 : 305 ~ 311 [2013]
  • Dermatology life quality index (DLQI): a simple practical measure for routine clinical use
    Finlay AY Clin Exp Dermatol 19 : 210 ~ 216 [1994]
  • Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis
    Griffiths CE N Engl J Med 362 : 118 ~ 128 [2010]
  • An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up
    Reich K J Drugs Dermatol 11 : 300 ~ 312 [2012]